Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and conveni
Contrasting Silo Pharma (NASDAQ:SILO) & MannKind (NASDAQ:MNKD)
02:18am, Friday, 21'st Nov 2025
MannKind (NASDAQ: MNKD - Get Free Report) and Silo Pharma (NASDAQ: SILO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies
MannKind to Present at the Jefferies Global Healthcare Conference
04:05pm, Tuesday, 11'th Nov 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CE
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
08:00am, Monday, 10'th Nov 2025
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a
MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
09:00am, Thursday, 06'th Nov 2025
$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Di
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
03:51pm, Wednesday, 05'th Nov 2025
MannKind Corporation ( MNKD ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Christopher Prentiss - Chief Financial Officer Conference Call P
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
10:36am, Wednesday, 05'th Nov 2025
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall St
MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
10:15am, Wednesday, 05'th Nov 2025
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
08:00am, Wednesday, 05'th Nov 2025
Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v.
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
04:05pm, Wednesday, 29'th Oct 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released befor
MannKind: Durable Cash Engine, Optional Catalysts Pending
12:55pm, Wednesday, 15'th Oct 2025
MannKind remains a Buy, driven by Tyvaso DPI's strong market position and Technosphere platform optionality. Tyvaso DPI continues robust growth despite Yutrepia's entry, with MNKD's Q2 share at $31 mi
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
09:02am, Tuesday, 07'th Oct 2025
DANBURY, Conn. and BURLINGTON, Mass.
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
09:00am, Tuesday, 07'th Oct 2025
DANBURY, Conn. and BURLINGTON, Mass.
